Screener
Ironwood Pharmaceuticals IRWD Total Cost of Revenue
Discontinued — last reported Q4 '20
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 16, 2023.
- Filed
- Feb 16, 2023
- Fiscal year
- FY2022
- Accession
- 0001558370-23-001462
| Line item | Years Ended December 31, 2022 | Years Ended December 31, 2021 | Years Ended December 31, 2020 |
|---|---|---|---|
| Sale of active pharmaceutical ingredient | — | 969 | 7,978 |
| Total revenues | 410,596 | 413,753 | 389,523 |
| Operating expenses: | |||
| Cost of revenues | — | — | 3,136 |
| Research and development | 44,265 | 70,405 | 88,062 |
| Selling, general and administrative | 115,994 | 111,133 | 140,003 |
| Restructuring expenses | — | (44) | 15,382 |
| Total operating expenses | 160,259 | 181,494 | 246,583 |
Item 16. Form 10-K Summary
FAQ
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.